Appropriate patient selection guides treatment planning in uHCC

NEXAVAR® (sorafenib) may be appropriate for a broad range of patients with uHCC1

In the SHARP trial, patients with uHCC included:

  • Child-Pugh class A (95%), class B (5%)

  • ECOG performance status 0-2

  • Portal vein invasion/extrahepatic spread (with or without)

  • Broad range of demographics

    • Europe and Australasia (88%)

    • North America (9%)

    • Central and South America (3%)

  • BCLC stage B and C

Sorafenib (NEXAVAR) is an NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) first-line systemic therapy option in patients with uHCC2

Appropriate HCC patient types (Child-Pugh class A [category 1] or B7 [category 2A])2

Unresectable
 because of inadequate hepatic
 reserve or tumor location

Inoperable because of
 performance status or
 comorbidity, local disease, or
 local disease with minimal
 extrahepatic disease only

HCC with metastatic
 disease or extensive liver
 tumor burden

National Comprehensive Cancer Network® (NCCN®) makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.

After NEXAVAR, consider STIVARGA® (regorafenib) to continue your HCC treatment plan3

Alt tag
Treatment Body

RESORCE (REgorafenib after SORafenib in patients with hepatoCEllular carcinoma) was an international, multicenter, randomized (2:1), double-blind, placebo-controlled trial that evaluated the efficacy and safety of STIVARGA in HCC patients with progression following NEXAVAR (N=573).3,4

  • Patients who permanently discontinued sorafenib therapy due to toxicity or who were unable to tolerate sorafenib doses of 400 mg once daily were ineligible for the RESORCE trial3

Indication for STIVARGA

STIVARGA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Important Safety Information

WARNING: HEPATOTOXICITY

  • Severe and sometimes fatal hepatotoxicity has occurred in clinical trials.

  • Monitor hepatic function prior to and during treatment.

  • Interrupt and then reduce or discontinue STIVARGA for hepatotoxicity as manifested by elevated liver function tests or hepatocellular necrosis, depending upon severity and persistence.
    Continue reading below